"name","uuid:ID","instanceType","rationale","description","id","label"
"Study Design 1","55a0afa8-dbb4-417d-9760-179cfffdbeef","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign_1",""
